CRESTONE Data Signal Positive Start to Treat Rare NRG1 Fusions in Solid Tumors

Retrieved on: 2022-08-01 17:18:27

Tags for this article:

Click the tags to see associated articles and topics

CRESTONE Data Signal Positive Start to Treat Rare NRG1 Fusions in Solid Tumors. View article details on hiswai:

Excerpt

Seribantumab, an anti-HER3 monoclonal antibody, ... Monoclonal antibodies target HER3 and HER2 when they treat NRG1-positive tumors.

Article found on: www.onclive.com